RBC Capital reiterates Pfizer stock Underperform rating at $25 By Investing.com

Pfizer’s tafamidis patent litigation with Hikma has been dismissed, and all four generic challengers (Dexcel, Aurobindo, Cipla, Hikma) have now exited the case, reducing near-term legal uncertainty around Vyndamax/Vyndaqel. Pfizer also reiterated its $0.43 quarterly dividend and has reached settlements that extend U.S. VYNDAMAX protection to June 1, 2031, though generic entry timing remains undisclosed. RBC maintained an Underperform rating with a $25 target, while Guggenheim stayed Buy at $36, highlighting mixed analyst sentiment.

Analysis

The market is likely underestimating how much optionality remains embedded in the tafamidis franchise even after the headline litigation noise. Once the last challenger is dismissed, the key driver shifts from courtroom risk to settlement economics: the first generic to strike a deal will anchor the rest, so the real catalyst is not trial outcome but the timing and structure of any reverse-payment or launch-stagger agreement. In practical terms, that means PFE should trade less on “patent won/lost” and more on how many quarters of exclusivity can still be monetized before price compression becomes visible in consensus models.

The second-order winner is not just Pfizer’s cash flow but its dividend narrative. A high payout becomes more defensible if litigation uncertainty clears, which can attract yield-sensitive capital even if growth remains mediocre; that can compress implied volatility and make downside protection cheaper after legal overhangs fade. The flip side is that any settlement that preserves protection only through 2031 will likely be treated by the street as a maintenance event, not an upside surprise, because the market has already started to model a slow-burn erosion curve rather than a cliff.

BCS and BBIO matter mainly as read-through names: broker sentiment can move around patent headlines, but the real trading opportunity is in the mismatch between legal-resolution headlines and commercial timing. If the market concludes that generic entry is still years away, the adverse move in PFE may reverse quickly as investors reprice longer-duration cash flows. If instead settlement terms quietly indicate earlier entry, the downside will likely show up first in 2027–2028 EPS estimates, not in the next quarter, making this a medium-horizon earnings-risk story rather than an immediate balance-sheet event.

Key Decisions for Investors

• Hold a tactical long PFE into legal-resolution clarity, but size modestly; the setup favors a 3-6 month re-rating if exclusivity is extended, with upside from multiple expansion more than fundamental growth.
• Buy downside protection on PFE only if implied vol is suppressed after the dismissal; use 6-9 month puts as a hedge against earlier-than-expected generic timing and estimate the trade as defined-risk insurance rather than outright bearish exposure.
• Pair trade: long PFE / short a basket of large-cap pharma with weaker yield support over a 3-6 month horizon, betting that patent clarity and dividend yield attract relative inflows even if absolute upside is limited.
• Avoid chasing BBIO on this headline alone; treat any move as a sympathy trade and look for a retracement entry only if the market overprices the patent read-through versus its actual exposure.
• If settlement language later implies launch before 2031, rotate from PFE equity into a short-dated bearish structure or trim longs immediately; the risk/reward flips fast once the market reprices terminal generic erosion.